AIM
EPZM

Alambic Investment Management’s Epizyme, Inc EPZM Stock Holding History

Alambic Investment Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-29,227
Closed -$557K – 536
2017
Q3 		$557K Buy
+29,227
New +$446K 0.06% 334

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Alambic Investment Management's EPZM Position: Q4 2017 in Review

Alambic Investment Management sold out of Epizyme, Inc (EPZM) in Q4 2017, closing a stake of 29,227 shares — an estimated $557K sold.

Alambic Investment Management first reported a position in EPZM in Q3 2017 and held it in 1 quarter. The position peaked at $557K in Q3 2017. 101 funds tracked by Wall St. Rank hold EPZM as of Q4 2017.

  • Alambic Investment Management reported no remaining Epizyme, Inc position as of Q4 2017 after selling out during the quarter.
  • Alambic Investment Management sold 29,227 Epizyme, Inc shares in Q4 2017, an estimated $557K.
  • Alambic Investment Management first reported a position in Epizyme, Inc in Q3 2017 and held it in 1 quarter.
  • Alambic Investment Management's Epizyme, Inc position peaked at $557K in Q3 2017.
  • 101 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2017.

Based on Alambic Investment Management's 13F filing for Q4 2017, filed 2 Feb 2018.